Lonza’s full-year core EBITDA up 20.7% on vaccine demand By Reuters
![Lonza's full-year core EBITDA up 20.7% on vaccine demand](https://i-invdn-com.investing.com/trkd-images/LYNXMPEI0P070_L.jpg)
© Reuters. FILE PHOTO: The logo of Swiss contract drug maker Lonza is seen at its headquarters in Basel, Switzerland October 1, 2020. REUTERS/Arnd Wiegmann
By Ludwig Burger
(Reuters) -Swiss drug contract manufacturer Lonza said core earnings gained 20.7% in 2021, shored up by demand for the substances it supplies for new mRNA COVID-19 vaccines.
Full-year core earnings before interest, tax, depreciation and amortisation (EBITDA) rose to 1.67 billion Swiss francs ($1.82 billion), up from 1.38 billion a year earlier, it said in a statement on Wednesday. That was broadly in line with an analyst consensus posted on its website.
The company, which is a key supplier of vaccine maker Moderna (NASDAQ:), is stepping up investments as it banks on long-term growth in the biopharmaceuticals sector well beyond the pandemic. [nL8N2R81GF]
For this year, Lonza predicted “low to mid-teens” sales growth, when excluding currency swings, as well as core EBITDA margin improvement from 30.8% in 2021.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Read More: Lonza’s full-year core EBITDA up 20.7% on vaccine demand By Reuters